Login to Your Account

PMV Pharma raises $74M series B for p53-focused cancer pipeline

By Michael Fitzhugh
Staff Writer

Thursday, February 23, 2017

PMV Pharmaceuticals Inc., a company developing cancer therapies to restore p53, a protein commonly mutated in tumors, has landed a $74 million series B financing.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription